Mendus: ADVANCE II survival data confirms positive MRD results - Redeye

Redeye comments on Mendus presenting ADVANCE II survival data at ASH 2022. The study had not yet reached median relapse-free survival after a median c19.4 months follow-up, indicating considerably better mRFS than historical QUAZAR AML-001 controls. We increase our estimated likelihood of approval for DCP-001 and valuation.

Länk till analysen i sin helhet: https://www.redeye.se/research/868864/mendus-advance-ii-survival-data-confirms-positive-mrd-results?utm_source=finwire&utm_medium=RSS